Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.36 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.36 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.36 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077360 | 1.00 | TRPV1 (0.41) | TRPV1SIGMAR1PDPK1LIPGPLAAT3 | |
| SCHEMBL6417430 | 0.85 | POLB (0.38) | PDPK1 | |
| SCHEMBL6417431 | 0.85 | POLB (0.38) | PDPK1 | |
| SCHEMBL6077470 | 0.85 | MEN1 (0.37) | SIGMAR1LIPG | |
| SCHEMBL6077465 | 0.85 | MEN1 (0.37) | SIGMAR1LIPG | |
| SCHEMBL6076726 | 0.85 | CDK8 (0.38) | SIGMAR1PDPK1 | |
| SCHEMBL6879362 | 0.82 | CDK8 (0.36) | TRPV1SIGMAR1PDPK1LIPG | |
| SCHEMBL6078367 | 0.82 | CDK8 (0.36) | TRPV1SIGMAR1PDPK1LIPG | |
| SCHEMBL6077308 | 0.82 | USP30 (0.47) | TRPV1SIGMAR1PDPK1 | |
| SCHEMBL6077313 | 0.82 | USP30 (0.47) | TRPV1SIGMAR1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | TRPV1 4770/4885SIGMAR1 4036/4885PDPK1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.